Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021

HomeFUNDINGMyra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings

Myra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings

Myra Vision, a Shifamed portfolio company, announced today the closing of its $17M Series A financings, which will be used to advance product development, scale infrastructure, and expand their team in order to support the development of the first of its kind glaucoma treatment device.

The financings were led by The Capital Partnership (TCP), with participation from Cormorant Asset Management and Shifamed angel investors. In conjunction with the financing, the company has changed its name to Myra Vision, Inc. from Myra Medical, Inc.

“We are extremely pleased to close this round of financing with strong support from our investors, validating the clear unmet need for a treatment that safely and efficiently achieves high intraocular pressure (IOP) reduction for moderate to severe glaucoma patients.” stated Robert Chang, CEO of Myra Vision. “Myra Vision’s innovative nanotechnology device is designed to allow physicians to safely maximize outflow to achieve optimized IOP reduction.”

Glaucoma, a leading cause of blindness, affects an estimated 66M people worldwide. More than one third of patients have moderate to severe glaucoma, which requires significant reductions in IOP. Traditionally, these patients have been treated with glaucoma surgery, including trabeculectomy and tube shunt implants. Recent advances in minimally invasive glaucoma surgery (MIGS) devices offer simpler and safer surgical treatment options. While the current MIGS devices have demonstrated an improvement in complication rates, they are not able to achieve the IOP reductions necessary for the moderate to severe glaucoma patient population.

“We are pleased to lead this round and believe Myra Vision’s next-generation technology has the potential to deliver a much-needed treatment for this large and underserved segment of the glaucoma market,” commented Casey Gordon, Head of Private Investments at TCP. “With Myra’s solution, physicians can personalize outflow depending on each patient’s evolving needs. We believe this will revolutionize care by vastly improving patient outcomes and satisfaction.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy